Press Releases

Press Releases (7)

CAMBRIDGE, Mass., October 4, 2017 – Semma Therapeutics, a biopharmaceutical company developing stem cell-derived islet (SC-islet) technology for type 1 diabetes (T1D), today announced it will present on its encapsulated stem cell-derived human islets in…
Read more
Highly Oversubscribed Financing Brings Together Leading Syndicate of Investors to Advance Clinical Development of Novel Cell Therapy for Type 1 Diabetes CAMBRIDGE, Mass., November 30, 2017 – Semma Therapeutics, a biotechnology company focused on the…
Read more
CAMBRIDGE, Mass., May 10, 2018 – Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the appointment of Bastiano Sanna, Ph.D., as Chief Executive Officer and…
Read more
CAMBRIDGE, Mass., March 22, 2017 – Semma Therapeutics, a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture…
Read more
CAMBRIDGE, Mass., November 7, 2016 – Semma Therapeutics, a biopharmaceutical company developing cellular therapies for the treatment of diabetes, announced today that Mark Fishman, M.D., has joined its Board of Directors as Chairman.
Read more